Wyeth and WHO launch Phase III trial for river blindness drug

Wyeth Pharmaceuticals has launched Phase III trials in three African countries to test reformulated animal antiparasitic moxidectin as a treatment for river blindness, a disease caused by the parasite Onchocerca volvulus that results in loss of sight, rashes and skin lesions.